Bizarre Patents
Decorative Jeweled Wheel Cover
An improved wheel is provided wherein decorative items such as gem stones are embedded in either the wheel surface, a special mounting section attached to the wheel surface, or to a spoke strap that wraps around each spoke and positions embedded gem stones on the outside surface of the spoke.
PatentStorm News
Make the Most of PatentStorm
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest patents by subscribing to an RSS feed.
Got questions? Ask a Patent Expert!
Registered users: Manage your profile, comments and alerts.
| Number | Title | Issue Date |
| 7662407 | Modified release formulations of a bupropion salt The present invention relates to pharmaceutical compositions, formulations and medicaments comprising a bupropion salt, in particular, modified-release tablets comprising an effective amount of bupropion hydrobromide, and the use of the bupropion salt to prepare a m... | 02/16/2010 |
| 7431944 | Delivery of multiple doses of medications Dosage forms for oral administration of a methylphenidate drug are provided. The dosage forms provide a substantially immediate dose of methylphenidate upon ingestion, followed by one or more additional doses at predetermined times. By providing such a drug release ... | 10/07/2008 |
| 7427413 | Stable shaped particles of crystalline organic compounds The present invention provides storage stable, shaped particles of allotropic organic compounds. The particles of the present invention can be shaped according to the desired application. Preferred shapes of such particles are microspheres, particularly those having... | 09/23/2008 |
| 7422758 | Sustained release vitamin composition A therapeutic formulation in the form of a beadlet, suitable for oral administration and adapted to provide immediate and sustained release of therapeutic material. Each beadlet comprises an extruded-spheronized inner core containing at least one medicament e.g. a s... | 09/09/2008 |
| 7419686 | Opioid agonist/antagonist combinations The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide ... | 09/02/2008 |
| 7387791 | Liposome drug delivery This invention comprises pharmaceutical compositions for administering a biologically active compound to an animal. Particularly provided are proliposomal compositions that are advantageously used to deliver biologically active compounds to the gastrointestinal trac... | 06/17/2008 |
| 7384653 | Oral dosage form comprising a therapeutic agent and an adverse-effect agent The present invention provides an oral dosage form comprising a first composition and a second composition. The first composition comprises an effective amount of a therapeutic agent and the second composition comprises an effective amount of an adverse-effect agent... | 06/10/2008 |
| 7374781 | Sustained release formulations containing acetaminophen and tramadol A sustained release formulation as a unit dose contains 100 mg-1000 mg of Acetaminophen and 15 mg-150 mg of tramadol hydrochloride, which comprises of 1) an immediate release portion comprising of 25%-75% of the total effective amount of drug in the dosage form and ... | 05/20/2008 |
| RE40300 | Carbon dioxide enhancement of inhalation therapy The present invention provides a method of increasing the deposition of aerosolized drug in the respiratory tract of an individual or animal, comprising the step of administering said aerosolized drug in an air mixture containing up to about 10% carbon dioxide gas. | 05/06/2008 |
| 7347850 | Adhesion barriers applicable by minimally invasive surgery and methods of use thereof Biocompatible crosslinked polymers, and methods for their preparation and use with minimally invasive surgery applicators are disclosed. The disclosure includes compositions and methods for in situ formation of hydrogels using minimally invasive surgical techniques.... | 03/25/2008 |
| 7348026 | Nanoparticles for targeting hepatoma cells The invention discloses the nanoparticles composed of γ-PGA-PLA block copolymers conjugated with galactosamine as a potential drug delivery system for treating liver cancers. ... | 03/25/2008 |
| 7323192 | Immediate release tablet An immediate release tablet is provided. The tablet comprises at least 60 weight % of an active ingredient and powdered wax having a melting point greater than about 90° C. The tablet may advantageously be produced by direct compression. Although the wax is hydroph... | 01/29/2008 |
| 7320802 | Methods of treatment using nanoparticulate fenofibrate compositions The present invention is directed to fibrate compositions having improved pharmacokinetic profiles and reduced fed/fasted variability. The fibrate particles of the composition have an effective average particle size of less than about 2000 nm. ... | 01/22/2008 |
| 7316821 | Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer A stabilized solid controlled release dosage form having a coating derived from an aqueous dispersion of ethylcellulose is obtained by overcoating a substrate including a therapeutically active with an aqueous dispersion of ethylcellulose and then curing the coated ... | 01/08/2008 |
| 7316818 | Liposome drug delivery of polycyclic, aromatic, antioxidant or anti-inflammatory compounds This invention comprises pharmaceutical compositions for administering a polycyclic, aromatic, antioxidant or anti-inflammatory compound to an animal. Particularly provided are proliposomal compositions that are advantageously used to deliver polycyclic, aromatic, a... | 01/08/2008 |
| 7314640 | Formulation and process for drug loaded cores The present invention relates to a controlled release pellet of metoprolol and its pharmaceutically acceptable salts that uses a water soluble or a water swellable inert starting seed or core. ... | 01/01/2008 |
| 7303765 | Ultrafine-L-carnitine, methods of preparing the same, compositions containing the same, and methods of using the same L-carnitine which has a particle size such that it substantially passes through a 100 USBS mesh sieve exhibits an increased bioavailability, a decreased hygroscopicity, and may be conveniently formulated with oil-based materials. ... | 12/04/2007 |
| 7282221 | Antiviral product, use and formulation thereof An antiviral product is comprised of at least three dosages forms, each of which has a different release profile, with the Cmax for the antiviral product being reached in less than about twelve hours. In one embodiment, there is an immediate release dosag... | 10/16/2007 |
| 7276249 | Nanoparticulate fibrate formulations The present invention is directed to fibrate compositions having improved pharmacokinetic profiles and reduced fed/fasted variability. The fibrate particles of the composition have an effective average particle size of less than about 2000 nm. ... | 10/02/2007 |
| 7217431 | Controlled agglomeration A process for the preparation of a particulate material by a controlled agglomeration method, i.e. a method that enables a controlled growth in particle size. The method is especially suitable for use in the preparation of pharmaceutical compositions containing a th... | 05/15/2007 |
| 7211275 | Composite materials for controlled release of water soluble products Composite materials comprising a water-soluble compound adsorbed onto a basic inorganic material and a bio-degradable polymer which yields acidic degradation products, methods of producing same, and methods of use thereof are described, wherein the composite materia... | 05/01/2007 |
| 7208460 | Multi component controlled delivery system for soap bars The present invention relates to an improved controlled delivery system that can be incorporated in soap bars to enhance deposition of active ingredients and sensory markers onto skin. The carrier system also provides controlled release or prolonged release of these... | 04/24/2007 |
| 7201891 | Pharmaceutical preparation for the diagnosis of helicobacter pylori infection A coated preparation for the detection of a H. pylori infection according to a urea breath test protocol which comprises a core composition containing at least an isotope C-labeled urea, an excipient and a lubricant in defined proportions and covered with 0.1... | 04/10/2007 |
| 7195769 | Pharmaceutical compositions of anti-tubercular drugs and process for their preparation A pharmaceutical composition of anti-tubercular drugs for oral use comprising Rifampicin and/or Isoniazid wherein the bioavailability of Rifampicin and/or other drugs is enhanced. Preferably the bioavailability of Rifampicin is enhanced by preventing its degradation... | 03/27/2007 |
| 7196093 | Reversible inhibitors of SAH hydrolase and uses thereof 1. The present invention provides compositions and methods for reversibly inhibiting S-adenosyl-L-homocysteine (SAH) hydrolase. The compounds of the present invention can be used as an anti-hemorrhagic viral infection agent, an immunosuppressant, a homocysteine lowe... | 03/27/2007 |
| 7186418 | Composition and use of RAR antagonists for promoting chondrogenesis The invention provides compositions comprising an RAR antagonist for promoting chondrogenesis and methods employing such compositions for treating cartilage and associated bone abnormalities resulting from injury or disease and for ex vivo tissue engineering. ... | 03/06/2007 |
| 7157103 | Pharmaceutical formulation containing irritant Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse; and an effective amount of an irritant to impart an irritating sensation to an abuser upon administration of said dosage form after ... | 01/02/2007 |
| 7157095 | Multiple-delayed release antifungal product, use and formulation thereof An anti-fungal product is comprised of at least three delayed release dosages forms, each of which has a different release profile, with the Cmax for the anti-fungal product being reached in less than about twelve hours after initial release of anti-funga... | 01/02/2007 |
| 7153840 | Aqueous fludarabine phosphate composition This invention is directed towards a ready-to-use aqueous composition of fludarabine phosphate. In one embodiment, the invention is directed to an aqueous fludarabine phosphate composition which comprises fludarabine phosphate, a base, and water. The concentration o... | 12/26/2006 |
| 7148207 | Oral fludara of high-purity formulation with quick release of active ingredient This invention relates to a quick-release tablet formulation with >99.19% pure fludara (high-purity fludara) as an active ingredient in a defined composition of residual contaminants. ... | 12/12/2006 |
| 7144587 | Pharmaceutical formulation containing opioid agonist, opioid antagonist and bittering agent Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of an opioid analgesic; an opioid antagonist; and a bittering agent in an effective amount to impart a bitter taste to an abuser upon administration of the dosage f... | 12/05/2006 |
| 7141250 | Pharmaceutical formulation containing bittering agent Disclosed in certain embodiments is an oral dosage form comprising a therapeutically effective amount of a drug susceptible to abuse; and an effective amount of a bittering agent to impart a bitter taste to an abuser upon administration of said dosage form after tam... | 11/28/2006 |
| 7138143 | Coated preparation soluble in the lower digestive tract A coating dispersion soluble in the lower digestive tract which is prepared by blending a hydroxypropyl methylcellulose acetate succinate (HPMCAS) soluble at around pH 7 with a conventional plasticizer and an anion surfactant and further adding an acid, wherein the ... | 11/21/2006 |
| 7122207 | High drug load acid labile pharmaceutical composition A high drug load spheronized beadlet is provided wherein said beadlet comprises about 80% to 100% by weight of an acid labile medicament, preferably didanosine, about 0% to about 10% by weight of a disintegrant, and about 0% to about 10% by weight of a binder select... | 10/17/2006 |
| 7122204 | Antibiotic composition with inhibitor Antibiotic composition having four dosage forms with different release profiles providing for initial release of a beta lactam antibiotic followed by release of a beta-lactamase inhibitor, followed by release of the antibiotic followed by release of the inhibitor. I... | 10/17/2006 |
| 7108866 | Chronotherapeutic diltiazem formulations and the administration thereof A controlled-release Galenical preparation of pharmaceutically acceptable Diltiazem including the pharmaceutically acceptable salts thereof, suitable for evening dosing every 24 hours containing from about 120 mg to about 540 mg or more (as desired) of the form of D... | 09/19/2006 |
| 7105174 | Multiple-delayed release anti-neoplastic product, use and formulation thereof An anti-neoplastic product is comprised of at least three delayed release dosages forms, each of which has a different release profile, with the Cmax for the anti-neoplastic product being reached in less than about twelve hours after initial release of an... | 09/12/2006 |
| 7098229 | (+)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions and uses thereof The present invention relates to (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable salts thereof, compositions comprising (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, and metho... | 08/29/2006 |
| 7097851 | Oral formulation for gastrointestinal drug delivery An oral formulation for gastrointestinal drug delivery which comprises an adhesion site-controlling layer for attaching the formulation to the selected site in the digestive tract, a drug-carrying layer for containing a drug and an adhesive and a protecting layer fo... | 08/29/2006 |
| RE39239 | Methods for treating early morning pathologies The present invention provides methods of treating early morning pathologies using a time-specific controlled release dosage formulation which is administered prior to sleep, and which permits or achieves delivery of a pharmaceutically active agent effective for the... | 08/15/2006 |